The C-X-C motif chemokine receptor 4 (CXCR4)/C-X-C motif chemokine ligand 12 (CXCL12) axis drives immune exclusion in pancreatic ductal adenocarcinoma (PDA). Building on our preclinical data, we conducted the first stage of an open-label, single-arm phase 2 clinical trial combining CXCR4 inhibition (motixafortide), PD-...
A. Raufi, Edridge K. D'Souza, Michael S. May et al.· Nature Communications· 0 citations
Spatial transcriptomics extends single-cell analysis of the tumor microenvironment into a mappable ecosystem by resolving gene expression in situ. Within it, cells assemble into recurrent multicellular niches whose spatial organization shapes tumor progression, immune evasion, and therapy response and resistance. Yet...
Álvaro Curiel-García, M. Franchini, L. Tomassoni et al.· Cancer Research· 0 citations
Oncogenic KRAS mutations are present in ∼95% of pancreatic ductal adenocarcinoma (PDAC) cases and have long been considered undruggable. The recent clinical emergence of RAS inhibitors marks a transformative moment in PDAC therapy, yet their impact on the tumor microenvironment (TME) remains largely unknown. This is...
Marie C. Hasselluhn, Allison C. Hess, L. Tomassoni et al.· Cancer Research· 0 citations
The authors apply ARACNe and metaVIPER to published scRNA-seq datasets to characterize pancreatic cancer subtypes, identifying six distinct cell states as well as their mechanistic determinants.
P. Laise, Mikko M. Turunen, Álvaro Curiel-García et al.· Nature Genetics· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
